Ruxolitinib Cream Shows Strong Efficacy and Reassuring Safety in New Analyses

As the role of topical Janus kinase (JAK) inhibition continues to evolve in dermatology, 2 posters presented at Winter Clinical Miami 2026 provide complementary insights into the clinical profile of ruxolitinib cream (Opzelura; Incyte Dermatology). One study offers a broad, integrated safety analysis across 20 clinical studies in inflammatory skin diseases,¹ while the other examines efficacy and safety in a particularly challenging population: adults with moderate atopic dermatitis (AD) who are candidates for systemic therapy.²

Together, the data presented through these posters address a central clinical question: can a topical JAK1/JAK2 inhibitor deliver robust efficacy while maintaining a reassuring safety profile—especially in light of classwide safety warnings associated with systemic JAK inhibitors? When ruxolitinib cream was approved by the FDA on September 21, 2021,³ it also received a boxed warning about several associated adverse health outcomes.⁴ It is currently approved in the US and Canada to treat AD in patients 2 years and older and in the US, Canada, the United Kingdom, Europe, and some European and Asian countries to treat nonsegmental vitiligo in patients 12 years and older.¹

Integrated Safety Across Studies

The first poster pooled safety data from 20 trials involving patients living with AD, alopecia areata (AA), hidradenitis suppurativa (HS), lichen planus (LP), lichen sclerosus (LS), and vitiligo.¹ Investigators calculated exposure-adjusted incidence rates (EAIRs) for adverse events included in the JAK inhibitor class warning: serious infections, major adverse cardiovascular events (MACE), thromboembolic events, malignancies (including nonmelanoma skin cancer [NMSC]), and mortality. For their investigation, EAIRs comprised number of patients experiencing an event per 100 person-years (PYs) of exposure.

Ten of the studies had investigated AD; 6, vitiligo; and 1 each, AA, HS, LP, and LS. Together, they accounted for more than 2000 PYs of exposure, with treatment durations that ranged from 4 weeks to 3 years. All patients applied 1.5% ruxolitinib cream twice daily.

Overall, pediatric patients with AD had an EAIR of 0.66 (95% CI, 0.08-2.37) per 100 PYs for serious infections only. There were no MACE, thromboembolic events, or malignancies. Adult patients with AD had EAIRs for serious infections (1.18; 95% CI, 0.38-2.75), MACE (0.24; 95% CI, 0.01-1.31), thromboembolic events (0.47; 95% CI, 0.06-1.70), NMSC (0.47; 95% CI, 0.06-1.70), and malignancies excluding NMSC (0.0; 95% CI, 0.0-0.87). Among patients with vitiligo, EAIRs trended similarly, with no MACE observed (0.0; 95% CI, 0.0-0.32) and identical low rates of serious infection, thromboembolic events, NMSC, and malignancies excluding NMSC (all, 0.35; 95% CI, 0.09-0.89).

No fatalities occurred in any study, and no patient with HS experienced any of the AEs under investigation. Plasma concentrations of ruxolitinib remained low across all of the studies, “well below the threshold of 281 nM associated with JAK-mediated myelosuppression using in vitro assays in whole blood in adults,” the study authors wrote.

Efficacy and Safety in Moderate AD

While the first poster addressed safety at scale, the second poster examined clinical performance in a population with significant unmet need, using data from the phase 3b TRuE-AD4 clinical trial (NCT06238817).² The trial evaluated the efficacy of ruxolitinib cream for moderate AD in patients with previous inadequate responses to, who could not tolerate, or who had contraindications to topical corticosteroids and topical calcineurin inhibitors.⁵ Patients were randomized 2:1 to twice-daily treatment of either 1.5% ruxolitinib cream (n = 160; median age, 39 years [range, 19-80]) or vehicle cream (n = 81; median age, 36.5 years [range, 19-88]) for 8 weeks, after which they could enter a 16-week extension period as needed. More than 50% of each group were female patients, and the median durations of disease were 18.5 years (range, 2.5-60.7) and 19.1 years (range, 2.2-58.1), respectively.

The adult population consisted of individuals diagnosed with AD at least 2 years prior; who had scores of 3 on the Investigator’s Global Assessment scale (IGA), above 7 on the Eczema Area and Severity Index 75 scale (EASI-75), 4 or higher on the itch Numerical Rating Scale (NRS), and above 10 on the Dermatology Life Quality Index; and who had 10% to 20% of their body surface area affected. Outcomes of interest were EASI-75 achievement (primary) and IGA score of 0 or 1, with at least a 2-point improvement (secondary).

By week 8, the rate of improvement via EASI-75 was almost 4 times greater in the ruxolitinib group vs the vehicle group (70.0% vs 18.5%; P < .0001). In addition, by week 2, improvements were already evident. Regarding depth of response, 27.3% of the treated cohort achieved clear skin via EASI-100, 59.1% achieved EASI-90, 72.7% achieved EASI-75, and 83.8% achieved EASI-50.

Pruritus improvements were also noteworthy. At the earliest, itch reduction was seen as soon as 15 minutes after application, with the 30-minute mark bringing nominal improvements. Then, by week 8, 62.5% of treated patients had achieved at least a 4-point improvement on the itch NRS vs 19.8% of vehicle patients (P < .0001). Also, mean DLQI and Patient-Oriented Eczema Measure scores saw significant improvement overall.

The authors concluded, “Ruxolitinib cream may therefore be an effective topical therapy option to delay or prevent progression to systemic therapy in patients with moderate AD.”

Takeaways

Taken together, these results^1,2 suggest that ruxolitinib cream offers a compelling balance: high levels of clinical efficacy—including deep and rapid responses—alongside low systemic exposure and a safety profile that, to date, does not mirror the risks associated with systemic JAK inhibitors. For clinicians now, the question is no longer simply if topical JAK inhibition works, but whether it can alter the treatment trajectory in moderate AD. Based on these posters, ruxolitinib cream may provide an opportunity to delay or even avoid systemic escalation for some patients, while maintaining a reassuring safety foundation grounded in both controlled trial data and extended follow-up.

References

1. Bunick CG, Ezzedine K, Eichenfield LF, et al. Integrated safety analysis of ruxolitinib cream: data from 20 clinical studies in inflammatory dermatologic conditions. Presented at: Winter Clinical Miami; February 27-March 1, 2026; Aventura, FL.
2. Carrascosa JM, Prajapati VH, Hong CH, et al. Efficacy and safety of ruxolitinib cream in adults with moderate atopic dermatitis: results from TRuE-AD4, a phase 3b, randomized, double-blind, vehicle-controlled study. Presented at: Winter Clinical Miami; February 27-March 1, 2026; Aventura, FL.
3. Satija B, Maddipatia M. FDA approves Incyte’s eczema cream with boxed warning. Reuters. September 21, 2021. Accessed March 2, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-incytes-eczema-cream-2021-09-21/
4. Issa NT, Kwong P, Bunick CG, Kircik L. Ruxolitinib 1.5% cream and the “boxed warning paradox”: reappraisal of safety through the lens of pharmacokinetics. J Drugs Dermatol. 2025;24(2):s16-s22. doi:10.36849/JDD.49143
5. A study to evaluate the efficacy, and safety study of ruxolitinib cream in adults with moderate atopic dermatitis (TRuE-AD4). ClinicalTrials.gov. Updated October 28, 2025. Accessed March 3, 2026. https://clinicaltrials.gov/study/NCT06238817